Algai Research LLC is pioneering advanced microalgae cultivation platforms—delivering precise RNA silica-lipid nanotherapeutics for neuromuscular diseases while scaling versatile multi-sector biomaterials.
Limb-girdle muscular dystrophy type 2A (LGMD2A/LGMDR1) is a life-debilitating, autosomal recessive neuromuscular disorder afflicting 80,000 people globally. It is caused by a missense mutation in CAPN3, a gene encoding calpain, a calcium-dependent cysteine protease vital for muscle health.
Our closed-loop cultivation architecture integrates high-tensile diatom biosilica and customized lipid envelopes. This enables scalable extraction of active therapeutic payloads alongside high-value co-products like thermo-gelling hydrocolloids and long-chain omega-3/omega-6 fatty acids.
By engineering fusogenic lipid associations combined with skeletal muscle-targeting peptides, our nanoparticles achieve direct cytoplasmic release and precise restoration of mutated genomic loci without systemic toxicity.
Traditional biologic manufacturing relies on expensive mammalian cell culture media. Our photosynthetic bioreactor arrays drive therapeutic production costs down while maintaining carbon-neutral operations.
By-products of our therapeutic microalgae synthesis are fractionated into high-purity omega fatty acids and specialized bio-polymers, turning agricultural waste streams into profitable commercial assets.
Beyond our flagship LGMDR1 theranostic pipeline, Algai’s proprietary microalgal biomaterial architecture and genetic expression platforms deliver profound commercial utility across five major industrial verticals:
Drug Delivery & Bio-Adhesives: Utilizing sulfated algal polysaccharides (alginates, carrageenans, ulvans) as pH-responsive hydrogel matrices for stable oral delivery and antimicrobial wound-healing coatings.
Rheology Modifiers: Modified microalgal exopolysaccharides (EPS) serve as high-performance, biodegradable biopolymers that maintain high viscosity and thermal stability in extreme subterranean brine environments.
Photoprotection & Emulsions: Sourcing high concentrations of mycosporine-like amino acids (MAAs) and astaxanthin for natural UV absorption, anti-aging antioxidants, and sustainable organic emulsion thickeners.
Whole-Cut Meat Analogues: Transgenic cyanobacteria engineered to naturally express fibrous protein strands, serving as high-protein scaffolding and 3D bioprinting bio-inks for alternative steaks and fillets.
Regenerative Medicine: Algae-derived hydrogels mimicking the extracellular matrix (ECM) for stem cell culture, muscle tissue regeneration, and hybrid lipid-polymer nanoparticles for nucleic acid delivery.
Paul oversees Algai’s corporate strategy, clinical commercialization roadmap, and intellectual property portfolios. He brings an extensive academic background, including completing his Master of Theological Studies at the University of Toronto and his foundational biological studies (BSCH, Biology) at Queen's University, where he received the Gold Medal in Biology. He also studied at the University of Calgary, earning Dean's List honors before pursuing medical studies at the University of Alberta and Queen's University.
View LinkedIn Profile →Philip specializes in turning visionary deep-tech into operational reality. He brings a rigorous, systems-level problem-solving approach from his Aerospace Engineering studies at the Royal Military College of Canada (RMC), combined with extensive experience in the financial sector managing capital allocation and risk for a private family trust. At Algai, he oversees daily operations, strategic scaling, and financial infrastructure.
View LinkedIn Profile →Dr. Wensel drives the technical architecture of Algai’s non-viral delivery systems and metabolic engineering pipelines. He holds a Ph.D. in Biological Systems Engineering from Washington State University and M.S. degrees in Chemical Engineering and Artificial Intelligence. His extensive background spans roles such as Chief Science Officer at Spira Inc., Manufacturing Systems Engineer at Merck, and Owner of Dronext.
View LinkedIn Profile →Dr. Kumaresan brings crucial expertise from her role as a Scientist in RNA Technical Operations at Aldevron, where she executed RNA Synthesis including In Vitro Transcription, enzymatic capping, and Poly(A) Tailing. Her extensive postdoctoral research includes isolating CD34+ hematopoietic stem cells at NDSU and reprogramming PBMCs into iPSCs at Western University.
View LinkedIn Profile →Anupam drives Algai's commercial strategy, bridging the gap between advanced RNA research and pharmaceutical industry development. He brings deep scientific experience from his roles at Millennium Pharmaceuticals, Acceleron Pharma, and Codexis, focusing on transfection optimization, directed enzyme evolution, and transgenic vector construction.
View LinkedIn Profile →Pawan leads the physical development of our automated laboratory screening hardware. He holds an MSc (Distinction) in Aeronautical/Aerospace Engineering from the University of Leicester and a BTech in Aerospace Engineering from Sandip University, with deep expertise in CFD, ANSYS, COMSOL, and CAD modeling.
View LinkedIn Profile →Rahul designs the genetic architectures at the core of our platform, engineering mRNA constructs and Prime Editing components necessary to restore CAPN3 functionality. He holds a Master's degree in Biotechnology from UAB and a Bachelor's degree in Microbiology from Bhavans New Science Degree College.
View LinkedIn Profile →